The London Free Press reports that more than 80 percent of employees admitted to taking a “mental health” day. Most people took the day (or days) off because of work-related stress. Others called out because they were tired, bored, or lacked motivation to go to work that day.
The Royal College of Psychiatrists published a report about a month ago that concluded abortions can lead to mental illness. This is significant considering that many psychiatrists in the mental health industry deemed carrying out an unwanted pregnancy to term far more of a mental health risk than getting an abortion. However, the report seems to be echoing old information: in 2006, the Journal of Child Psychology and Psychiatry arrived at the same conclusion in young women who had abortions.
At last, New York victims of the 9/11 attack are getting assistance with their mental health benefits. Newsday reports that the benefit program “will reimburse out-of-pocket costs for mental health or substance-use treatment through a claims process similar to any insurance benefit.” These costs include outpatient services, medication related to treatment, lab work, and psych evaluations.
Unfortunately, the benefit only applies to those living in the New York City boroughs or are workers of the city. Anyone from NYC who’s curious to find out about whether they’re eligible can dial 311 or go to www.nyc.gov/9-11mentalhealth.
Finally, in more sad military news, the Veterans Health Administration admitted that about 18 vets a day—126 per week—commit suicide. This news comes on the heels of the study that found mental illness is increasing (or is being identified better) in U.S. troops.
As more info on Pristiq continues to roll out, I'll do my best to track them quite closely.
While Wyeth scrambles to resolve issues in its Puerto Rico plant to meet FDA standards, Ms. Kathleen Kerr of Newsday recently reported on Pristiq's potential to be approved for use in depression and hot flashes resulting from menopause. I was so excited to see some decent reporting on a mental health issue in a paper other than the NYT. It was also nice to see that it didn't end with "Shares of Wyeth fell 38 cents Friday to close at $51.50 on the New York Stock Exchange."
"If Pristiq wins Food and Drug Administration approval, it will be the first antidepressant and only non-hormonal remedy marketed specifically for hot flashes. But Pristiq isn't without problems – it poses rare suicide risks in young people."
Continue reading “Pristiq's FDA Chances: Depression – Yea; Menopause – Nay”
NAMI is touting a new atypical… in the press release for Johnson & Johnson. Michael J. Fitzpatrick, executive director of NAMI lent a statement in J&J’s pr about Risperdal’s sibling, Invega. *sniff, sniff* Something smells fishy about this. Makes me wonder if these non-profits bag money from Big Pharma under the table… (source: Furious Seasons)
An electronic ping sent from Sprint to the police helped save the life of a college student who tried to commit suicide, according to Newsday. A ping also helped save the lives of James Kim’s wife and children after getting stuck in the mountains of Oregon. This ping thing is interesting. Especially since Newsday needs to put quotes around it because ping isn’t a real vocabulary word… yet.
Merry Christmas to all and to all a good night.
ADDENDUM: Oooh, ooh, ooh – just found out: Any family that has a minor who may have consumed Paxil or Paxil CR is eligible for a stake in a $63.8 million settlement with GlaxoSmithKline. More info about the settlement at paxilpediatricsettlement.com. Apparently, it seems as though GSK covered up information about the medications’ safety and efficacy. This is one I’d like to learn more about considering I’ve been on Paxil. Not as a minor but the settlement raises questions regarding GSK withholding information about Paxil’s safety and efficacy regarding adults.
Is it now fashionable to sue pharma companies for not making all of their information public?